Charles Riv Labs Intl Inc Stock Price, News & Analysis

Charles River Laboratories (NYSE: CRL) has announced a collaboration with Sanofi to develop Virtual Control Groups (VCGs) in nonclinical toxicology. This initiative aims to reduce the use of animals in research by replacing some control group animals with data-driven virtual counterparts created from historical datasets. Guided by Charles River’s Alternative Methods Advancement Project (AMAP), this collaboration leverages machine learning and extensive data to generate meaningful study results without the need for as many animal subjects. The project is a pioneering effort to apply VCGs, commonly used in clinical trials, to preclinical research, involving partnerships with regulatory and biopharmaceutical leaders. The initiative aims to advance sustainable science in toxicology studies.

Charles River Laboratories (NYSE: CRL) will present at two upcoming conferences. The company will speak at the William Blair 44th Annual Growth Stock Conference on June 4th at 10:00 a.m. CT (11:00 a.m. ET) and at the Jefferies Global Healthcare Conference on June 5th at 10:00 a.m. ET. Management will discuss the company's strategic priorities, business developments, and industry trends. Live webcasts and replays will be available on the Investor Relations section of Charles River's website.

Charles River Laboratories has launched new Modular and Fast Track viral vector technology transfer frameworks. These frameworks are designed for seamless tech transfer to its Maryland-based viral vector Center of Excellence within nine months. The Fast Track framework allows for straightforward transfers when no process changes are needed, while the Modular framework supports complex transfers requiring process modifications. Both frameworks aim to prevent costly delays and ensure program success. Charles River's CoE offers full-scale capabilities for adeno-associated virus, adenovirus, lentivirus, and retrovirus production and integrates their concept-to-cure portfolio from discovery to commercialization.

Charles River Laboratories reported first-quarter 2024 results with revenue of $1.01 billion, GAAP EPS of $1.30, and Non-GAAP EPS of $2.27. The company updated its 2024 guidance and reaffirmed revenue growth and non-GAAP earnings per share estimates. Despite revenue declines in the DSA segment, the RMS and Manufacturing segments showed growth. The company aims to capitalize on new business opportunities in the biopharmaceutical sector.

Charles River Laboratories International, Inc. (NYSE: CRL) has launched viral vector reference materials to aid gene and cell therapy researchers, providing AAV and LVV products with high quality. The company aims to streamline the research and development process, offering superior serotypes and vector genome concentrations. The launch includes six AAV reference material serotypes and five LVV reference material products, contributing to their extensive CDMO offerings. The official launch will take place at the ASGCT Annual Meeting in May 2024, showcasing case study data and various presentations. Charles River's CGT portfolio and viral vector CDMO solutions aim to support client programs and assist in scaling from pre-clinical to commercial stages.